- Regulus Therapeutics (NASDAQ:RGLS): Q2 GAAP EPS of -$0.08 in-line.
- As of June 30, 2021, Regulus had $41.4 million in cash and cash equivalents.
- Shares +0.78%.
- Press Release
Regulus Therapeutics EPS in-line
Recommended For You
More Trending News
About RGLS Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| RGLS | - | - |
| Regulus Therapeutics Inc. | ||